In line with this, other researcher found that EGFR-inhibited surviving metastatic CRC cells exhibited reduced EGFR ligand expression, enhanced HER2/HER3 signaling pathway activity, and sustained activation of the phosphatidylinositol 3-kinase (PI3K) pathway in the PDX model (Venturini et al., 2024). The gene discussed is ERBB2; the disease is colorectal carcinoma.